Document Detail

Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
MedLine Citation:
PMID:  22994348     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: The impact of sublingual immunotherapy (SLIT) on IgE neosensitization remains to be evaluated in large cohorts of patients.
OBJECTIVES: The aim of this study was to assess the dynamics of antibody responses induced in patients with allergic rhinitis during a 12-month treatment with sublingual tablets of house dust mites (HDM) allergen extracts.
METHODS: Antibody responses were assessed in relationship with neosensitization and clinical benefit in sera from 509 European house dust mite-allergic patients before and after 1 year of daily sublingual immunotherapy, using tablets containing Dermatophagoides pteronyssinus plus D farinae extracts or placebo ( NCT00674700). Patients were followed for one additional year after treatment cessation. IgE and IgG4 antibodies specific for mite extracts or purified group 1, 2 and 10 allergens were assessed using Immulite, Immunocap and ISAC assays.
RESULTS: After 1 year of SLIT, mite-specific IgE and IgG4 titres increased by 1.5-fold and fourfold, respectively, in the active, but not in the placebo group. A strong IgG4 induction occurred in a subgroup (i.e. 10-15%) of "immunoreactive" patients, without any correlation with improvement in the average adjusted symptom score. Pre-existing IgE levels to purified mite allergens were not impacted during immunotherapy, and no de novo IgE responses to group 1, 2, 10 allergens were induced in patients who were unsensitized prior to immunotherapy. Similarly, no IgE neosensitization to wheat germ or yeast components used in the mite culture medium was observed.
CONCLUSIONS AND CLINICAL RELEVANCE: We document in a cohort of 509 patients followed over a 2-year period that SLIT does not induce any IgE neosensitization to allergens contained in the vaccine, such as groups 1, 2 as well as the food-related group 10 allergen. This observation further corroborates the safer safety profile of SLIT over SCIT.
V Baron-Bodo; T Batard; H Nguyen; M Fréreux; S Horiot; C Harwanegg; K C Bergmann; O de Beaumont; P Moingeon
Related Documents :
23057708 - Experience with a novel, single handpiece, multi-modal fractional ablative co2 laser fo...
24593838 - Efficacy and safety of low molecular weight heparin in patients with mechanical heart v...
24678638 - Posterior lumbar interbody fusion with stand-alone trabecular metal cages for repeatedl...
23316358 - A retrospective analysis of the clinical impact of 939 chest radiographs using the medi...
9069728 - Do triage nurse-initiated x-rays for limb injuries reduce patient transit time?
14584858 - Factors influencing the outcome of regenerative therapy in mandibular class ii furcatio...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology     Volume:  42     ISSN:  1365-2222     ISO Abbreviation:  Clin. Exp. Allergy     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8906443     Medline TA:  Clin Exp Allergy     Country:  England    
Other Details:
Languages:  eng     Pagination:  1510-8     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Stallergenes SA, 6 rue Alexis de Tocqueville, 92183, Antony Cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Trends in cutaneous sensitization in the first 18 years of life: results from the 1989 Isle of Wigh...
Next Document:  Contribution of regulatory T cells to alleviation of experimental allergic asthma after specific imm...